Lifecome Biochemistry (002868.SZ) announced the performance forecast for the first half of 2024. According to preliminary calculations by the finance department, it is expected to incur a net loss of 50-65 million yuan attributable to shareholders of the listed company in the first half of 2024, compared with a loss of 46.6652 million yuan in the same period last year. Deducting non-recurring gains and losses, the net loss is expected to be 85-98 million yuan, compared with a loss of 65.8977 million yuan in the same period last year. Basic loss per share is expected to be 0.32-0.42 yuan/share; operating revenue is expected to be 0.36-0.38 billion yuan, compared with 0.23 billion yuan in the same period last year.
The main reason for the company's performance change this period is: 1. Regarding the company's photovoltaic film business, compared to the investment and construction of the same period last year, this year it has turned into trial production and production capacity climbing and customer import stages of EVA and EPE films. In addition, the price of photovoltaic film raw material particles has continued to fall since this year, and the company has made provision for the devaluation of inventory film particles. Taking into account the above factors, the photovoltaic film business has correspondingly increased the loss of about 40 million yuan; 2. Regarding the company's veterinary drug business, due to the increase in sales and the improvement of product technology, the loss has decreased by about 40 million yuan compared to the same period last year.